The Cellular Response to Hypoxia in Cancer White paper

January 19, 2019

Tissue hypoxia exerts significant influence on molecular programs, cellular properties and in tumors often leads to aggressive phenotypes. HIF-1α and HIF-2α belong to the family of hypoxia inducible transcription factors and mediate cellular reprograming under low oxygen conditions. HIFs are stabilized under hypoxia and regulate the expression of genes involved in key cellular adaptations including angiogenesis, metabolic switch and stemness.

Spotlight

BioReliance

As part of the Sigma-Aldrich Corporation, operating under the SAFC Commercial business unit, BioReliance is a key component of the Company's commercial life science services portfolio. With locations worldwide, BioReliance offers more than 1,000 tests and complementary services related to biologics safety testing and specialized toxicology

OTHER WHITEPAPERS
news image

How Can Biotechnology and Pharmaceutical Industries Better Weather This New Economy?

whitePaper | October 10, 2022

Biotechnology and pharmaceutical industries continue to experience increased pressure on financial performance due to several factors.

Read More
news image

Producing therapeutic peptides using biotechnology

whitePaper | October 20, 2022

We began the project by working to the design of a recombinant bacterial strain selection of a strain capable of producing high concentrations of peptides.

Read More
news image

Next-Generation Technology, Procedures, and Products Facilitate Biopreservation Best Practices for Cellular Therapies.

whitePaper | August 19, 2022

The quality of procedures and products used for preparing, transporting and storing cells at cryogenic temperatures have a direct impact on post-thaw viability and functionality, as well as the consistency and reliability of biological agents from a Quality perspective.

Read More
news image

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Read More
news image

How advanced purification technologies are speeding the hunt for new protections against disease

whitePaper | November 24, 2022

Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.

Read More
news image

GMP Grade PMSF and Protease Inhibitors

whitePaper | February 23, 2023

Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis.

Read More

Spotlight

BioReliance

As part of the Sigma-Aldrich Corporation, operating under the SAFC Commercial business unit, BioReliance is a key component of the Company's commercial life science services portfolio. With locations worldwide, BioReliance offers more than 1,000 tests and complementary services related to biologics safety testing and specialized toxicology

Events